CVM Stock Discussion
Cel-Sci Corporation Description
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Immune System Immunotherapy Vaccines Autoimmunity Rheumatoid Arthritis Vaccination Transplantation Cytokine Head And Neck Cancer Antigen Immune Response Allergies
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Popular Now
Featured Articles